Long COVID in children: A closer look reveals lasting impacts

A comprehensive review in Pediatrics highlights the significant impact of post-acute sequelae of SARS-CoV-2 (PASC) in children, revealing a wide range of long-term symptoms and the need for further research on its prevalence, risk factors, and mechanisms.

Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG) – Biotech Investments

Xlife Sciences AG / Key word(s): Alliance/Strategic Company Decision 30-Sep-2024 / 20:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

October 1, 2024

COVID-19 vaccines reduce infection and complications in pregnant women

The reactogenicity and impact of coronavirus disease 2019 (COVID-19) vaccines on pregnancy outcomes.

June 18, 2024

Digital health deals rallied in the first half of 2024, though funding still trails last year

Digital health startups raised $5.7 billion in the first half of 2024, slightly less than the $6.1 billion in the same period in 2023, according

July 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.